Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128354 | 0.86 | ALDH1A1 (0.52) | HCAR2ALDH1A1LMNATSHRESR1 | |
| SCHEMBL129566 | 0.80 | — | — | |
| SCHEMBL6062638 | 0.80 | HCAR2 (0.41) | HCAR2ALDH1A1LMNATSHRESR1 | |
| SCHEMBL204763 | 0.80 | POLB (0.44) | HCAR2ALDH1A1LMNATSHRESR1 | |
| SCHEMBL131854 | 0.79 | HCAR2 (0.38) | HCAR2ALDH1A1LMNATSHRESR1 | |
| Hydrochloric Acid SCHEMBL29154726 | 0.78 | POLB (0.43) | HCAR2ALDH1A1LMNATSHRESR1 | |
| SCHEMBL4672467 | 0.78 | HCAR2 (0.40) | HCAR2ALDH1A1LMNATSHRESR1 | |
| SCHEMBL27984406 | 0.78 | HCAR2 (0.40) | HCAR2ALDH1A1LMNATSHRESR1 | |
| SCHEMBL4672465 | 0.78 | HCAR2 (0.40) | HCAR2ALDH1A1LMNATSHRESR1 | |
| SCHEMBL129864 | 0.77 | HCAR2 (0.36) | HCAR2ALDH1A1LMNATSHRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832082-B1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-11-21 | — | — | EP | claimed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | claimed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101394742-A | Anthranilamide derivatives and their use for the control of insects and acari | SYNGENTA PARTICIPATIONS AG (CH) | 2009-03-25 | — | — | CN | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| CN-101370786-A | Substituted imidazoles and their use as pesticides | PFIZER LTD (GB) | 2009-02-18 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-0832082-B1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| US-6258817-B1 | PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | ZENECA LTD. (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6060475-A | Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof | ZENECA LIMITED (GB) | 2000-05-09 | — | — | US | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | HCAR2 99/4885ALDH1A1 580/4885LMNA 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.